NCT07294508 2026-03-20
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Recruiting
Clinical Trials
8 trialsNCT07294534 2025-12-19
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06891833 2025-10-02
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT02568839 2020-08-13
PREDIX HER2
Karolinska University Hospital
Phase 2/3 Active not recruiting
NCT02581462 2020-08-11
PETRARCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed